Concurrent substance use among cancer patients with and without a history of cannabis use since cancer diagnosis at an NCI-Designated Cancer Center in Florida.

Background: Although substance use may have adverse impacts on cancer outcomes, little is known regarding patterns of concurrent substance use with cannabis among cancer patients. Our objective was to examine predictors of concurrent substance use with cannabis among cancer patients since their cancer diagnosis and explore perceptions of cannabis among these patients.

Methods: Patients treated at a National Cancer Institute-designated comprehensive cancer center were invited to participate in an electronic survey regarding medical cannabis from August to November 2021.

Cannabis use and patient-reported outcomes among patients at a comprehensive cancer center.

Background: Patients with cancer report increasing rates of cannabis use, often to manage symptoms and toxicities. The efficacy and safety of cannabis, however, for some use cases remains unclear. To better understand characteristics of patients with cancer who report using cannabis, we examined data from a cannabis use survey of among patients with cancer seen at a National Cancer Institute-Designated Cancer Center.

Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study.

Background: There has been limited study regarding patient-provider communication about medical cannabis for cancer symptom management. To address this gap, this study assesses the determinants and prevalence of patient-provider communication about the use of medical cannabis for cancer symptoms at a National Cancer Institute-designated Comprehensive Cancer Center.

Methods: Individuals who completed cancer treatment from July 2017 to December 2019 were invited to participate in a survey regarding medical cannabis.

Clinical and descriptive characteristics associated with high-grade meningioma in a large clinical series.

Purpose: We studied 571 patients with intracranial meningioma for clinical characteristics and tumor location associated with high grade meningioma (WHO II/III).

Materials And Methods: Patients were participants in a multicentre epidemiologic study of risk factors for primary brain tumors including meningioma recruited from September 2005 to November 2019. We included patients 18 or older with a recent diagnosis of a primary intracranial meningioma of any subtype (ICD9/10: 9530-0, 9531-0, 9532-0, 9537-0, 9533-0, 9534-0, 9530-0, 9538-1, 9538-3) who were enrolled at neuro-oncology and neuro-surgery clinics in the southeastern U.

Associations of gut microbiome with endogenous estrogen levels in healthy postmenopausal women.

Purpose: The gut microbiome is a potentially important contributor to endogenous estrogen levels after menopause. In healthy postmenopausal women, we examined associations of fecal microbiome composition with levels of urinary estrogens, their metabolites, and relevant metabolic pathway ratios implicated in breast cancer risk.

Methods: Eligible postmenopausal women (n = 164) had a body mass index (BMI) ≤ 35 kg/m and no history of hormone use (previous 6 months) or cancer/metabolic disorders.

Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women.

Purpose: Circulating estrogens are an established risk factor for postmenopausal breast cancer (BCa). We describe the distribution of urinary estrogens, their metabolites, and relevant metabolic pathway ratios among healthy postmenopausal women and examine associations of several known BCa factors with these estrogen measures.

Methods: Eligible postmenopausal women (n = 167) had no history of hormone use (previous 6 months) and cancer/metabolic disorders and had a body mass index (BMI) ≤ 35 kg/m.

Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women.

Purpose: We examined gut microbiome (GM) profiles in relation to mammographic breast density (BD) and body mass index (BMI) in healthy postmenopausal women.

Methods: Eligible women were postmenopausal, had a BMI ≤ 35 kg/m, and had not recently taken oral/IV antibiotics. All women provided a fecal sample and information on breast cancer risk factors.

LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women.

In order to undertake an epidemiologic study relating levels of parent estrogens (estrone and estradiol) and estrogen metabolites (EMs) to other breast cancer risk factors, we have optimized methods for EM quantification with ultra high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). A two-step approach was adopted; the first step comprised method development and evaluation of the method performance. The second step consisted of applying this method to quantify estrogens in postmenopausal women and determine if the observed patterns are consistent with the existing literature and prior knowledge of estrogen metabolism.

Concordance of cancer related concerns among advanced cancer patient-spouse caregiver dyads.

To describe advanced cancer patient-spouse caregiver couples' cancer-related concerns, determine dyadic concordance of concerns, and predict concordance based on demographic characteristics. Secondary analysis of cross-sectional self-report data. 88 advanced cancer patients and spouse self-identified caregivers.

Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida.

Glioma is a devastating primary tumor of the central nervous system with difficult-to-manage symptoms. Cannabis products have been postulated to potentially benefit glioma patients. Recent state legalization allowed investigators an opportunity to study glioma patients' adoption of medical marijuana (MM).